Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Outlook for the Neutralizing Antibody Market Heading Into 2029?

The increase in the market size of neutralizing antibodies in the past few years has been quite significant. It is projected to expand from $230.25 billion in 2024 to $257.81 billion in 2025, with a compound annual growth rate (CAGR) of 12.0%. Factors such as an upsurge in the approval of biologics, increased funding for antibody research, a higher incidence of chronic viral infections, growing knowledge of immunotherapy, and elevated healthcare expenditure can be credited for the expansion witnessed in the historical period.

Over the next few years, there is a projection for a swift growth in the market size of neutralizing antibodies. It is anticipated that by 2029, it will escalate to $401.16 billion, with a compound annual growth rate (CAGR) of 11.7%. The growth during the forecast period is likely to be driven by increasing instances of emerging infectious diseases, a rise in autoimmune disorders, an expansive pipeline of antibody-based therapies, the surging demand for precision medicine, and an augmenting demand for targeted therapies. Prominent trends during the projected period include a shift towards the use of bispecific and multispecific antibodies, the application of artificial intelligence (AI) in the discovery of antibodies, the development of antibody-drug conjugates, increased usage of plant-based production of antibodies, and the upswing in personalized immunotherapies.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24620&type=smp

Which Factors Are Pushing The Neutralizing Antibody Market Forward?

The increasing occurrence of infectious diseases is predicted to fuel the expansion of the neutralizing antibody market. Such diseases are illnesses prompted by harmful microorganisms like bacteria, viruses, fungi, or parasites, which are capable of spreading from one person to another directly or indirectly. The escalating frequency of these diseases can be attributed to heightened travel, allowing for the quick transmission of pathogens across borders. Neutralizing antibodies bolster the treatment of these diseases by specifically identifying and neutralizing pathogens – this makes them effective in averting the progression of the disease. They enhance patient outcomes by providing accurate and prompt immune protection. To exemplify, the UK Health Security Agency, a government agency within the UK, reported in February 2024 that tuberculosis cases (a contagious bacterial disease primarily impacting the lungs) in England escalated to 4,850 in 2023 from 4,380 cases a year prior – a rise of 10.7%. As such, the escalating occurrence of infectious diseases is driving the expansion of the neutralizing antibody market.

Which Segment Held The Largest Share In The Neutralizing Antibody Market In 2025?

The neutralizing antibody market covered in this report is segmented –

1) By Antibody Type: Monoclonal Antibodies, Polyclonal Antibodies

2) By Target Virus: SARS-CoV-2 (COVID-19), Human Immunodeficiency Viruses (HIV), Influenza, Ebola, Zika, Hepatitis C, Other Target Viruses

3) By Distribution Channel: Direct Sales To End-Users, Distributors, Online Retail, Other Distribution Channels

4) By Application: Therapeutics, Diagnostics, Research And Development

5) By End User: Hospitals And Clinics, Research Institutes, Diagnostic Laboratories, Pharmaceutical Companies, Other End Users

Subsegments:

1) By Monoclonal Antibodies: Fully Human Monoclonal Antibodies, Humanized Monoclonal Antibodies, Chimeric Monoclonal Antibodies, Murine Monoclonal Antibodies

2) By Polyclonal Antibodies: Animal-Derived Polyclonal Antibodies, Recombinant Polyclonal Antibodies, Human Polyclonal Antibody Preparations

How Are Key Trends Driving Expansion In The Neutralizing Antibody Industry?

Leading enterprises in the neutralizing antibody market are concentrating their efforts on creating sophisticated remedies like targeted therapies, designed to fight off infectious diseases by accurately neutralizing viruses and blocking their access to human cells. Targeted therapies essentially refer to treatments that zoom in on molecular markers or pathways that are vital for the proliferation and survival of disease-causing cells such as cancerous cells or viruses. For instance, U.S.-based pharmaceutical firm Eli Lilly and Company was granted Emergency Use Authorization (EUA) by the U.S. Food and Drug Administration (FDA) for Bebtelovimab, a targeted neutralizing monoclonal antibody therapy against COVID-19, in February 2022. Bebtelovimab is crafted to treat patients with a mild to moderate severity of COVID-19 who are at a high probability of advancing to severe conditions, including hospitalization or death. This authorization facilitates timely treatment in the face of burgeoning viral variants, bolstering efforts to mitigate disease severity and enhance patient outcomes.

Which Organizations Are Driving Progress In The Neutralizing Antibody Industry?

Major companies operating in the neutralizing antibody market are Pfizer Inc., Johnson & Johnson, Roche Holding AG, Merck & Co. Inc., AstraZeneca PLC, Sanofi SA, GlaxoSmithKline plc, Eli Lilly and Company, Regeneron Pharmaceuticals Inc., GeNext Genomics, Celltrion Healthcare Co. Ltd, BeiGene Ltd, AbCellera Biologics Inc., BMC Pharmacology and Toxicology, Anthos Therapeutics, Immunome Inc., Sorrento Therapeutics Inc., Tonix Pharmaceuticals, Abwiz Bio, AXIM Biotechnologies.

Get The Full Report Here:

https://www.thebusinessresearchcompany.com/report/neutralizing-antibody-global-market-report

Which Region Is Expected To Experience The Highest Growth In The Neutralizing Antibody Industry?

North America was the largest region in the neutralizing antibody market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neutralizing antibody market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=24620&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model